NEW YORK , July 22, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC Â (the "M&A Class Action Firm"), has recovered millions of dollars for...
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
NEW YORK , July 14, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC Â (the "M&A Class Action Firm"), has recovered millions of dollars for...
MILWAUKEE , July 14, 2026 /PRNewswire/ -- Ademi LLP is investigating NextCure (NASDAQ: NXTC) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior...
Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as...
BELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer,...
55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg) Favorable safety and tolerability...
SIM0505/CDH6 ADC dose optimization initiated in gynecologic cancers SIM0505 Phase 1 dose escalation study data to be presented at ASCO 2026 LNCB74 Phase 1 dose escalation trial update planned in...
Dose optimization will initially be focused on evaluating SIM0505 in patients with platinum-resistant ovarian cancer (PROC)Â Phase 1 data readout to be presented at ASCO 2026 BELTSVILLE, Md.,...